217 related articles for article (PubMed ID: 15208680)
21. Regulation of c-Raf-1: therapeutic implications.
Beeram M; Patnaik A; Rowinsky EK
Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
[TBL] [Abstract][Full Text] [Related]
22. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
23. Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase.
Tian S; Mewani RR; Kumar D; Li B; Danner MT; Ahmad I; Rahman A; Notario V; Dritschilo A; Kasid UN; Gokhale PC
Int J Oncol; 2006 Oct; 29(4):861-7. PubMed ID: 16964381
[TBL] [Abstract][Full Text] [Related]
24. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
[TBL] [Abstract][Full Text] [Related]
25. IGFBP7 is not required for B-RAF-induced melanocyte senescence.
Scurr LL; Pupo GM; Becker TM; Lai K; Schrama D; Haferkamp S; Irvine M; Scolyer RA; Mann GJ; Becker JC; Kefford RF; Rizos H
Cell; 2010 May; 141(4):717-27. PubMed ID: 20478260
[TBL] [Abstract][Full Text] [Related]
26. RAF expression in human astrocytic tumors.
Hagemann C; Gloger J; Anacker J; Said HM; Gerngras S; Kühnel S; Meyer C; Rapp UR; Kämmerer U; Vordermark D; Flentje M; Roosen K; Vince GH
Int J Mol Med; 2009 Jan; 23(1):17-31. PubMed ID: 19082503
[TBL] [Abstract][Full Text] [Related]
27. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Garnett MJ; Rana S; Paterson H; Barford D; Marais R
Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
[TBL] [Abstract][Full Text] [Related]
28. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Jilaveanu LB; Zito CR; Aziz SA; Conrad PJ; Schmitz JC; Sznol M; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2009 Sep; 15(18):5704-13. PubMed ID: 19737955
[TBL] [Abstract][Full Text] [Related]
29. The brothers RAF.
Kwong LN; Chin L
Cell; 2010 Jan; 140(2):180-2. PubMed ID: 20141832
[TBL] [Abstract][Full Text] [Related]
30. Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
Blair CM; Walsh NM; Littman BH; Marcoux FW; Baillie GS
BMC Cancer; 2019 Mar; 19(1):266. PubMed ID: 30909892
[TBL] [Abstract][Full Text] [Related]
31. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
Smalley KS
Int J Cancer; 2003 May; 104(5):527-32. PubMed ID: 12594806
[TBL] [Abstract][Full Text] [Related]
32. How blocking Raf activates the MAPK pathway.
McCormick F
Pigment Cell Melanoma Res; 2010 Apr; 23(2):187-9. PubMed ID: 20128874
[No Abstract] [Full Text] [Related]
33. V599EB-RAF is an oncogene in melanocytes.
Wellbrock C; Ogilvie L; Hedley D; Karasarides M; Martin J; Niculescu-Duvaz D; Springer CJ; Marais R
Cancer Res; 2004 Apr; 64(7):2338-42. PubMed ID: 15059882
[TBL] [Abstract][Full Text] [Related]
34. Relief of inhibitory autophosphorylation activates RAF.
Cancer Discov; 2013 Jul; 3(7):OF31. PubMed ID: 23847376
[TBL] [Abstract][Full Text] [Related]
35. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
[TBL] [Abstract][Full Text] [Related]
36. RAF kinase inhibitors in cancer treatment: like a bull in a China shop?
Robubi A; Waldmann H; Rauh D
Chembiochem; 2010 Aug; 11(12):1645-8. PubMed ID: 20648512
[No Abstract] [Full Text] [Related]
37. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin.
Molhoek KR; Brautigan DL; Slingluff CL
J Transl Med; 2005 Oct; 3():39. PubMed ID: 16255777
[TBL] [Abstract][Full Text] [Related]
38. RAF antisense oligonucleotide as a tumor radiosensitizer.
Kasid U; Dritschilo A
Oncogene; 2003 Sep; 22(37):5876-84. PubMed ID: 12947394
[TBL] [Abstract][Full Text] [Related]
39. Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
Niculescu-Duvaz I; Roman E; Whittaker SR; Friedlos F; Kirk R; Scanlon IJ; Davies LC; Niculescu-Duvaz D; Marais R; Springer CJ
J Med Chem; 2006 Jan; 49(1):407-16. PubMed ID: 16392826
[TBL] [Abstract][Full Text] [Related]
40. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Grbovic OM; Basso AD; Sawai A; Ye Q; Friedlander P; Solit D; Rosen N
Proc Natl Acad Sci U S A; 2006 Jan; 103(1):57-62. PubMed ID: 16371460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
